GERON CORP (GERN) 3.295 0 (-0.15%)
3.295 0 (-0.15%)
US3741631036 - Common Stock
GERON CORP3.295
NASDAQ:GERN (2/1/2023, 10:34:03 AM)0 (-0.15%)
| GICS Sector | Health Care | ||
| GICS Industry | Biotechnology | ||
| Valuation | Growth | ||
| Profitability | Health | ||
| Dividend | |||
| Earnings (Last) | 11-03 2022-11-03/bmo | Earnings (Next) | 03-08 2023-03-08 |
| Ins Owners | 0.13% | Inst Owners | 43.24% |
| Market Cap | 1.44B | Shares | 437.11M |
| PE | N/A | Fwd PE | N/A |
| Dividend Yield | N/A | Analysts | 86.67 |
| IPO | 07-31 1996-07-31 | ||
Stock Screener Links
Nasdaq Stock Screener
Find more stocks on Nasdaq
USA Stock Screener
Find more stocks on the USA
GICS Sector Stock Screener
Find competitors from the same sector on the USA
GICS Industry Stock Screener
Find competitors from the same industry on the USA
Technical Stock Screener
Find stocks with similar TA and Setup ratings on the USA
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Technical Competitors Stock Screener
Find the competitors with the best technical ratings on the USA
Best Technical Setups Competitors Stock Screener
Find the competitors with the best technical and setup ratings on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA
Company Profile
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 69 full-time employees. The firm operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).The Company has completed the evaluation of safety, tolerability, pharmacokinetics and pharmacodynamic effects of Imetelstat in its Phase I trials.
Company Info
GERON CORP
919 East Hillsdale Boulevard, Suite 250
Foster City CALIFORNIA 94404
P: 16504737700.0
CEO: John A. Scarlett
Employees: 69
Website: https://www.geron.com/
GERN News
8 days ago - InvestorPlace7 A-Rated Stocks to Buy for Less Than $25These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.
9 days ago - Market News VideoFirst Week of September 15th Options Trading For Geron
13 days ago - Geron CorporationGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 days ago - Geron CorporationGeron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference
21 days ago - Seeking AlphaGERN stock sets commercial leadership for imetelstat launch (NASDAQ:GERN)Geron Corporation (GERN) announced new additions to its senior commercial leadership on Wednesday ahead of the planned launch of blood cancer therapy imetelstat. Read the full story here.
21 days ago - Geron CorporationGeron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.GERN Twits
Here you can normally see the latest stock twits on GERN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
